Cerebral Amyloid Angiopathy
eMedicine, Jan, Menon, R.S., 2012
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Thalamic Astasia from Isolated Centromedian Thalamic Infarction
Neurol 78:146-147, Elwischger,K.,et al, 2012
Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012
Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012
Serologic Diagnosis of NMO
Neurol 78:665-671, Waters,P.J.,et al, 2012
Central Nervous System Involvement in Dengue
Neurol 78:736-742, Araujo,F.M.C.,et al, 2012
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Inflammatory Cortical Demyelination in Early Sclerosis
NEJM 365:2188-2197, Lucchinetti, C.F.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Epidemic Profile of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany
NEJM 365:1771-1780, Frank, C.,et al, 2011
Syndrome of Inappropriate Antidiuresis May Herald or Accompany Neuromyelitis Optica
Neurol 77:1644-1645, Iorio, R.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Yellow Fever Vaccination and Increased Relapse Rate in Travelers with Multiple Sclerosis
Arch Neurol 68:1267-1271, Farez, M.F. and Correale, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Clinical Characteristics of Pediatric-onset Neuro-Behcet Disease
Neurol 77:1900-1905, Uludiz, D.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
A Strange Case of Waitress Headache
Lancet 378:1824, Libera, D.D.,et al, 2011
Ring Sign on Diffusion-Weighted Imaging
Arch Neurol 68:1474, Finelli, P.F. and Uphoff, D.F., 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
A Clinical Prediction Rule for Ambulation Outcomes After Traumatic Spinal Cord Injury: A Longitudinal Cohort Study
Lancet 377:1004-1010, 972, van Middendorp,J.J,et al, 2011
Beh�et Disease: Evolution of Clincal Manifestations
Medicine 90:125-132, Ideguchi,H.,et al, 2011
Clinical and Functional Outcome and Factors Predicting Prognosis in Osmotic Demyelination Syndrome (Central Pontine and/or Extrapontine Myelinolysis) in 25 Patients
JNNP 82:326-331, Kallakatta,R.N.,et al, 2011
Prior Suggestive Symptoms in One-Third of Patients Consulting for a "First" Demyelinating Event
JNNP 82:323-325, Gout,O.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Paraneoplastic isolated myelopathy Clinical course and neuroimaging clues
Neurol 76:2089-2095, Flanagan, E.P.,et al, 2011
Predicting motor outcome and death in term hypoxic-ischemic encephalopathy
Neurol 76:2055-2061, Martinez-Biarge, M.,et al, 2011